tiprankstipranks
Analyst Profile
Followed by 95 other investors
.
Reni Benjamin

Reni Benjamin

JMP Securities
Wall Street Analyst
Ranked #7,754 out of 8,019 Analysts on TipRanks (#20,723 out of 21,482 overall experts)

Success Rate

38%
147 out of 391 Profitable Transactions

Average Return

-5.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Reni Benjamin's ratings since 2009 and opened each position for the duration of 1 Year:
37.60% of your transactions would have been profitable with an average return of -5.8%

Stock Rating Distribution

822Ratings
81.14% Buy
18.61% Hold
0.24% Sell
Distribution of Reni Benjamin's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
CTI BioPharma Corp.
(CTIC)
Rating Type:Buy
Dates:Dec 01, 2021 - Jan 01, 1970
Gain:248.10%
The most profitable rating made by Reni Benjamin

Reni Benjamin's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Dendreon Corp
Buy
Reiterated
0.00%
1
Sciclone Pharmaceuticals
Buy
Reiterated
0.00%
2
Aeterna Zentaris
Buy
Reiterated
0.00%
2
Geron
Buy
Reiterated
$9.00
(282.98% Upside)
0.00%
2
Sarepta Therapeutics
Hold
Downgraded
$39.00
(-64.22% Downside)
0.00%
1
KBR
Buy
Initiated
$17.00
(-67.76% Downside)
0.00%
1
Palisade Bio
Hold
Reiterated
0.00%
3
Pharmacyclics
Buy
Initiated
0.00%
1
OncoSec Medical
Buy
Reiterated
$40.00
(5298.84% Upside)
0.00%
6
Agenus
Buy
Reiterated
$6.00
(102.02% Upside)
0.00%
6
List of latest recommendations made by Reni Benjamin. Click to expand and see Reni Benjamin's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More